A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC

被引：0
|
作者：
Li, J. [1 ]
机构：
[1] Sichuan Prov Canc Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
stage III nonsmall cell lung cancer; neoadjuvant immunotherapy; low dose radiation therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P29.07
引用
收藏
页码：S1049 / S1050
页数：2
相关论文
共 50 条
  • [1] Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
    Li, J.
    Li, Q.
    Lu, S.
    Jiang, L.
    Li, L.
    Xie, S. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S158 - S159
  • [2] Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study
    Li, Juan
    Lu, Shun
    Tian, Yuke
    Jiang, Lan
    Li, Lu
    Xie, Shao-Hua
    Li, Qiang
    RADIOTHERAPY AND ONCOLOGY, 2024, 196
  • [3] A phase Ib trial of neoadjuvant chemoradiotherapy and durvalumab (MEDI4736) for potentially resectable stage III non-small cell lung cancer (NSCLC)
    Ahn, B. C.
    Lee, S.
    Seo, J. W.
    Lee, C. Y.
    Lee, J. G.
    Park, S. Y.
    Kim, D. J.
    Lee, C. G.
    Cho, J.
    Yoon, H. I.
    Shim, B. Y.
    Cho, D. G.
    Kim, S. W.
    Park, H. S.
    Chun, Y. J.
    Hong, M. H.
    Kim, H. R.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 601 - 601
  • [4] Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
    Lee, Jiyun
    Cho, Jaeho
    Lee, Chang
    Lee, Chang Young
    Lee, Jin Gu
    Kim, Dae Joon
    Shim, Hyo Sup
    Lim, Sun Min
    Kim, Hye Ryun
    Cho, Byoung Chul
    Hong, Min Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
    Heymach, J.
    Taube, J.
    Mitsudomi, T.
    Harpole, D.
    Aperghis, M.
    Trani, L.
    Powell, M.
    Dennis, P.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S625 - S626
  • [6] Neoadjuvant Chemoimmunotherapy in Potentially Resectable Stage III NSCLC
    Zhu, Donghui
    Yao, Yuanshan
    INDIAN JOURNAL OF SURGERY, 2024, 86 (06) : 1325 - 1325
  • [7] Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC
    Jiang, G.
    Zhang, P.
    Li, Q.
    Chen, H.
    Xie, S.
    Zhang, H.
    Ruan, Z.
    Xia, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S273 - S273
  • [8] AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
    Schumann, C.
    Heymach, J. V.
    Harpole, D.
    Mitsudomi, T.
    Taube, J. M.
    Galffy, G.
    Hochmair, M.
    Winder, T.
    Zukov, R.
    Garbaos, G.
    Gao, S.
    Kuroda, H.
    You, J.
    Lee, K. -Y.
    Antonuzzo, L.
    Aperghis, M.
    Doherty, G. J.
    Mann, H.
    Fouad, T. M.
    Reck, M.
    Weissinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 8 - 9
  • [9] Comparision of Neoadjuvant Chemoimmunotherapy and Chemotherapy for Potentially Resectable Stage IIIA/B NSCLC
    Ma, K.
    Xu, Y.
    Chen, X.
    Wang, Y.
    Zhao, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S573 - S573
  • [10] Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Hong, M. H.
    Ahn, B.
    Kim, H. R.
    Lim, S. M.
    Lee, S.
    Park, S. Y.
    Lee, C. Y.
    Lee, J. G.
    Kim, D. J.
    Lee, S. H.
    Yoon, H. I.
    Lee, C. G.
    Cho, J.
    Shim, H. S.
    Kim, T.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S194 - S195
12345